Michael Goodman, M.D., F.A.C.P., Curriculum Vitae - Glacier Oncology

CURRICULUM VITAEMichael Gordon Goodman, M.D.EducationYale University, New Haven, Connecticut, 1964-1968, B.A.University of California School of Medicine, San Francisco, California, 1968-1972, M.D.Professional RecordMedical Intern, University of Miami School of Medicine, Miami, Florida, 1972-1973Medical Resident I, Thomas Jefferson University Hospital, Philadelphia, Pa., 1973-1974Medical Resident II, UCLA/Wadsworth Veterans Administration Hosp, Los Angeles, CA1974-1975Research Fellow, Department of Immunopathology, Scripps Clinic and Research Foundation, LaJolla, California, 1975-1978Clinical Fellow, Division of Hematology and Oncology, Department of Medicine, Scripps Clinicand Research Foundation, La Jolla, California, 1992-1994Assistant Member I, Dept. of Immunopathology, Scripps Clinic and Res. Fdn., 1978-1980Assistant Member II, Dept. of Immunopathology, Scripps Clinic and Res. Fdn., 1980-1982Assistant Member, Dept. of Immunology, Scripps Clinic and Res.Fdn., 1982-1983Associate Member with Tenure, Dept. of Immunology, The Scripps Research Institute, 1983-1996Adjunct Physician, Dept. of Medicine, Division of Hematology/Oncology, Scripps Clinic andResearch Foundation, 1994-1996Attending Physician, Dept. of Medicine, Kalispell Regional Medical Ctr, Kalispell, MT, 1996-presentAttending Physician, North Valley Hospital, White Fish, MT, 1997- present.

Chief, Section of Oncology, Kalispell Regional Medical Center, Kalispell, MT, 1997-1999CEO and President, Glacier Oncology, PLLC, Kalispell, MT, 1997-present.Honors and AwardsDepartmental Honors with Exceptional Distinction, Yale University, 1968Graduation cum laude, Yale University, 1968Ranking Scholar, Yale University, 1966-1968; Dean's List, Yale Univ. 1964-1965,1966-1968United States Public Health Service, Summer Medical Student Research Award, 1969-1970United States Public Health Service National Research Service Award 1975-1978Arthritis Foundation Fellowship, 1978-1980United States Public Health Service, National Institutes of Health Research CareerDevelopment Award, 1980-1985Medical LicensureCaliforniaMontanaProfessional ListingsABMS Directory of Board Certified Medical SpecialistsAmerican Men and Women of ScienceWho's Who in Frontier Science and TechnologyWho's Who in Science and EngineeringWho's Who in the WestCertificationDiplomate, American Board of Internal Medicine, Subspecialty Boards in Medical Oncology

Diplomate, American Board of Internal Medicine, Specialty Boards in Internal MedicineDiplomate, National Board of Medical ExaminersProfessional OrganizationsFellow, American College of PhysiciansMember, American Society of Clinical OncologyMember, American Society of Internal MedicineMember, The New York Academy of SciencesMember, The American Association of ImmunologistsMember, The American Association of PathologistsMember, Montana Medical AssociationInvestigator, Montana Cancer ConsortiumInvestigator, South West Oncology GroupInvestigator, Montana Society of Clinical OncologyProfessional Journals RefereedNatureThe Journal of Clinical InvestigationThe Journal of Biological ChemistryThe Journal of ImmunologyBloodCellular ImmunologyThe Journal of Immunological MethodsClinical Immunology and ImmunopathologyImmunopharniacologyArchives of Pathology and Laboratory MedicineInternational Journal of ImmunopharniacologyHepatologyProceedings of the Society for Experimental Biology and MedicineJournal of Clinical ImmunologyBiochemistryJournal of ImmunotherapyProstaglandinsCommitteesCo-Chairman, International Meeting on Nucleosides and Lymphocytes, sponsored by Office ofNaval Research, October 1984, Boston, Massachusetts

Staff Liaison, Division of Animal Resources, Scripps Clinic and Research Foundation, La Jolla,California, April 1986-1992Committees (continued)Member, Animal Research Committee, Scripps Clinic and Research Foundation, 1986-1992Member, Nonhuman Primate Research Committee, Scripps Clinic and Research Fdn 1986-92Reviewer, Advisory Committee, Medical Biochemistry Study Section, National Institutes ofHealth, 1987,1988Reviewer, National Science Foundation, 1982Reviewer, Arthritis Society of Canada, 1985-1996Advisor, World Health Organization, Geneva, Switzerland, 1990Member, Clinical Protocol Committee, Scripps Clinic and Research Foundation, 1992-1996National Cancer Institute Site Visit Committee Member, Advisory Committee, National Institutesof Health, 1994-1996.Member, Clinical Protocol Committee, Kalispell Regional Medical Center, Kalispell, MT, 1997-presentMember, Radiation Oncology Review Commitee, Kalispell Regional Med Center, Kalispell, MTChief, Section of Oncology, Kalispell Regional Medical Center, Kalispell, MT, 1997-1999Member, Kalispell Regional Medical Center General Tumor Board, 2010 -presentMember, Kalispell Regional Medical Center Breast Tumor Board, 2010 - presentClinical Trials Designed1. A Phase I study of the safety, pharmacokinetics and immunologic effects of loxoribine (7-allyl-8-oxoguanosine) in patients with advanced malignancies who have failed standard therapy. B.Meisenberg, D.L. McKee, M.G. Goodman. Scripps Clinic and Research Fdn.2. Loxoribine—a phase I/II study of the safety, pharmacokinetics, and immunologic effects inpatients with advanced, previously treated chronic lymphocytic leukemia. M.P Kosty, L.D.Piro, and M.G. Goodman. Scripps Clinic and Research Foundation.

3. Immunophenotypic and Functional assessment of the lymphohematopoietic system before andafter high-dose chemotherapy and autologous stem cell support. B. Meisenberg, M.G.Goodman, D.L. McKee. Scripps Clinic and Research Foundation.Clinical Trials Designed (continued)4. A Phase I/II study of the pharmacokinetics and immunologic efficacy of loxoribine (7- allyl-8-oxoguanosine) in patients with metastatic melanoma who have failed standard therapy. B.Meisenberg, M.G. Goodman, D.L. McKee. Scripps Clinic and Research Fdn.5. A dose-escalation study of the immunologic efficacy of loxoribine (7-allyl-8-oxoguanosine) inpatients with common variable immunodeficiency disease. M. G. Goodman, R. Simon.Scripps Clinic and Research Foundation.Industrial Consultant ActivityOrtho Pharmaceutical Corp. of Johnson and Johnson, New Brunswick, N. J. 1981-1992.Cytotec, Inc., San Diego, California 1984-86.La Jolla Pharmaceuticals, La Jolla, California 1991.Metra Biosystems, Palo Alto, California 1992.Sandoz Pharmaceuticals, Ltd, Basel Switzerland. 1995.Preceptorship Lecture Series, Green Cancer Center, Scripps ClinicAmgen Corporation, Thousand Oaks, California, 1993-1996.Immunex Corporation, Seattle, Washington, 1993-1996.Community ActivitiesMember, Yale Alumni Schools Committee, 1986-1994Member, La Jolla-UCSD Symphony and Chorus. 1977-1978, 1989-1996Member, Glacier Chorale. 1996-1999

Issued U.S. Patents1. Goodman, M.G., and W.O. Weigle. Modulation of animal cellular responses withcompositions containing 8-substututed guanine derivatives. Filed November 9, 1982, SerialNo. 439,846. Patent issued Sept. 3,1985. Patent No. 4,539,205.2. Goodman, M.G., and W.O. Weigle. Modulation of animal cellular responses withcompositions containing 8-substituted guanine derivatives. Filed November 1, 1983. SerialNo. 546,679. Patent issued February 17,1987. Patent No. 4,643,992.3. Goodman, M.G. Antimicrobial chemotherapeutic potentiation using substituted nucleosidederivatives. Filed November 15, 1985. Serial No. 798,629. Patent issued May 24, 1988.Patent No. 4,746,651.4. Goodman, M.G., and W.O.Weigle. Modulation of animal cellular responses withcompositions containing 8-substituted guanine derivatives. Filed Feb 13, 1987. Serial No.14,618. Patent issued July 18,1989. Patent No. 4,849,411.5. Goodman, M.G. Modulation of animal cellular responses with compositions containingisoxanthopterin-8-(r-beta-aldoglycosidyl) derivatives. Filed Dec. 12, 1986. Serial No.154,991. Patent issued Feb. 13,1990. Patent No. 4,900,675.6. Goodman, M.G., and W.O. Weigle. Modulation of animal cellular responses withcompositions containing 8-substituted guanine derivatives. Filed June 6, 1989. Serial No.361,974. Patent issued Aug. 14,1990. Patent No. 4,948,730.7. Goodman, M.G., W.O. Weigle, S. Bell, R. Chen, R. Robins, and W.J. Hennen.Immunostimulating guanine derivatives, compositions and methods. Filed May 5, 1988.Serial No. 190,697. Patent issued April 30,1991. Patent No. 5,011,828.8. Goodman, M.G., and R. Chen. Immunostimulating guanosine derivatives and theirpharmaceutical compositions. Filed May 5,1988. Serial No. 190,694. Patent issued March 3,1992. Patent No. 5,093,318.9. Goodman, M.G., and W. O. Weigle. Modulation of animal cellular responses withcompositions containing 8-substituted guanine derivatives and interferons. Filed August 2,1990. Serial No. 562,101. Patent issued Sept. 15, 1992. Patent No. 5,147,636.10. Goodman, M.G., and E.P. Gamson. Immunostimulating 7-deaza-7-oxa and 7-deaza-7-oxoanalogs of 8-substituted-guanine-9-(r-beta-D-aldoglycosidyl) derivatives and methods oftreating test animals. Filed May 24, 1988. Serial No. 07/198,141. Patent issued Nov. 24,1992. Patent No. 5,166,141.

(continued)11. Goodman, M.G., and W.O. Weigle. Modulation of animal cellular responses withcompositions containing 8-substituted guanine derivatives. Filed Sept. 15, 1992. Serial No.07/945,215. Patent issued May 31,1994. Patent No. 5,317,013.12. Chen, R., M.G. Goodman, and A. Reitz. N9 morpholino derivatives of 7,8-disubstitutedguanines. Filed May 27, 1994. Serial No. 250,484. Patent issued January 17, 1995. PatentNo. 5,382,580.13. Chen, R., M.G. Goodman, and A. Reitz. N9 morpholino derivatives of 7,8-disubstitutedguanines. Filed Jan. 17, 1995. Serial No. 8/373,374. Patent issued August 8, 1995. PatentNo. 5,439,907.14. Goodman, M.G., R. Chen, and A. Reitz. 2',3l-dideoxy-2',3'-didehydro derivatives of 7,8-disubstituted guanines. Filed May 27, 1994. Serial No. 08/250,483. Patent issued Aug. 15,1995. Patent No. 5,441,942.15. Goodman, M.G., and L.D. Piro. Cancerous B cell treatment using substituted nucleosidederivatives. Filed November 12, 1993. Serial No. 08/151,142. Patent issued Dec. 19, 1995.Patent No. 5,476,659.16. Reitz, A., M.G. Goodman, R. Chen, and B.E. Maryanoff. N9 alkyl or aralkyl derivatives of7,8-disubstituted guanines. Filed August 27, 1996. Serial No. 08/703,578. Patent issued July28, 1998. Patent No. 5,786,359.

PUBLICATIONSMichael G. Goodman, M.D.1. Painter, R.B., M.G. Goodman and B. Reisner. The effect of ultraviolet light on RNAmetabolism in BUdR-grown HeLa cells. Photochem. Photobiol 12:49,1970.2. Bricker, L., P. Kozlovskis and M.G. Goodman. Negative feedback in sterol biosynthesis andlipoprotein release by the perfused rat liver. Proc. Soc. Exp. BioL Med. 143:375,1973.3. Goodman, M.G. and W.O. Weigle. Nonspecific activation of murine lymphocytes. I.Proliferation and polyclonal activation induced by 2-mercaptoethanol and a-thioglycerol. J.Exp. Med. 145:473,1977.4. Goodman, M.G., D.C. Morrison and W.O. Weigle. Modulation of lipopolysaccharide(LPS)-mediated function by structural differences of two physically distinct fractions ofEscherichiacoli K235 LPS. J. Immunol 118:1852,1977.5. Goodman, M.G., D.E. Parks and W.O. Weigle. Immunologic responsiveness of the C3H/HeJmouse: Differential ability of butanol-extracted lipopolysaccharide (LPS) to evokeLPS-mediated effects. J. Exp. Med. 147:800,1978.6. Goodman, M.G. and W.O. Weigle. Nonspecific activation of murine lymphocytes. II.Parameters of the interaction between splenic lymphocytes and radiolabeled2-mercaptoethanol in vitro. J. Immunol. 120:1453,1978.7. Goodman, M.G., J.M. Fidler and W.O. Weigle. Nonspecific activation of murinelymphocytes. III. Cells responding mitogenically to 2-mercaptoethanol are typicalunstimulated lymphocytes. J. Immunol 121:189,1978.8. Goodman, M.G., J.M. Fidler and W.O. Weigle. Nonspecific activation of murinelymphocytes. IV. Proliferation of a distinct, late-maturing lymphocyte subpopulation inducedby 2-mercaptoethanol. J. Immunol 121:1905,1978.9. Goodman, M.G. and W.O. Weigle. Nonspecific activation of murine lymphocytes. V. Roleof cellular collaboration between T and B lymphocytes in the proliferative and polyclonalresponses to 2-mercaptoethanol. J. Immunol 122:1433,1979.10. Goodman, M.G. and W.O. Weigle. Nonspecific activation of murine lymphocytes. VI.Mediation of synergistic interaction between T and B lymphocytes by a cell-associated,reciprocally acting lymphocyte proliferation helper. J. Exp. Med. 149:644,1979.11. Goodman, M.G. and W.O. Weigle. T cell regulation of polyclonal B cell responsiveness. I.Helper effects of T cells. J. Immunol. 122:1548, 1979.

12. Goodman, M.G. and W.O. Weigle. T cell regulation of polyclonal B cell responsiveness. II.Evidence for a deficit in T cell function in mice with an X-linked B lymphocyte defect. J.Immunol. 123:2484,1979.13. Goodman, M.G., W.O. Weigle and T.E. Hugh. Inability of the C3a anaphylatoxin topromote cellular lysis. Nature (London) 283:78,1980.14. Goodman, M.G. and W.O. Weigle. Inability of T cells from mice with the CBA/N B-celldefect to amplify polyclonal B-cell responses to bacterial lipopolysaccharide. din. Immunol.Immunopath. 15:375, 198015. Goodman, M. G. and W. O. Weigle. Modulation of lymphocyte activation. I. Inhibition byan oxidation product of arachidonic acid. J. Immunol. 125:593, 1980.16. Goodman, M. G. and W. O. Weigle. Regulation of the immune response. In TheHandbook of Cancer Immunology, Vol. 17 (H. Waters, ed.) Garland STPM Press, NewYork, p. 51,1981.17. Goodman, M. G., L. L. Brunton and W.O. Weigle Modulation of lymphocyte activation. II.Alteration of intracellular cyclic nucleotide concentrations by an oxidation product ofarachidonic acid. Cell. Immunol. 59:95, 1981.18. Goodman, M.G. and W.O. Weigle. Inhibition of lymphocyte mitogenesis by an arachidonicacid hydroperoxide. J. Supramol. Struct., No. 3, 13:373, 1980.19. Goodman, M.G. and W.O. Weigle. Nonspecific activation of murine lymphocytes. VII.Functional correlates of molecular structure of thiol compounds. J. Immunol. 126:20,1981.20. Goodman, M.G. Cellular aspects of polyclonal activation of B lymphocytes. ImmunologyToday 1:92, 1980.21. Goodman, M.G. and W.O. Weigle. T cell regulation of polyclonal B cell responsiveness. III.Overt T helper and latent T suppressor activities from distinct subpopulations of unstimulatedsplenic T cells. J. Exp. Med. 153:844, 1981.22. Goodman, M. G. and W. O. Weigle. Role of polyclonal B cell activation in self-nonselfdiscrimination. Immunology Today'2:54, 1981.23. Walker, S.M. and M.G. Goodman. Specific immune responses. In Immunobiology of theHead and Neck (J.F.Poliquin, A.F.Ryan and J.Harris, eds) College Hill Press, San Diego,pp.83-102,1984.

24. Goodman, M.G. and W.O. Weigle. Inhibition of lymphocyte mitogenesis by an arachidonicacid hydroperoxide. In Control of Cellular Division and Development, Part A (D.Cunningham, E. Goldwasser, J. Watson and C.F. Fox, eds.) Alan R.Liss, Inc. New York, p.87, 1981.25. Goodman, M.G. and W.O. Weigle. Cellular regulation of non-specific (non-antigenic) Blymphocyte activation. Arch. Pathol. Lab. Med. 105:565, 1981.26. Goodman, M.G. and W.O. Weigle. Activation of lymphocytes by brominated nucleoside andcyclic nucleotide analogues: Implications for the "second messenger" function of cyclic GMP.Proc. Natl. Acad. Sci. USA 78:7604, 1981.27. Goodman, M.G. and W.O. Weigle.Nonspecific activation of murine lymphocytes. VIII.Effects of D-penicillamine. Cell. Immunol. 65:337,1981.28. Goodman, M.G. and W.O. Weigle. The role of regulatory components from resident Tlymphocytes inpolyclonal B cell activation. J. Cell Biochem. 18:395, 1982.29. Chenoweth, D.E., M.G. Goodman and W.O. Weigle. Demonstration of a specific receptorfor human C5a anaphylatoxin on murine macrophages. J.Exp.Med. 156:68,1982.30. Goodman, M.G. and W.O. Weigle. Induction of immunoglobulin secretion by a simplenucleoside derivative. J. Immunol. 128:2399,1982.31. Goodman, M.G., D.E. Chenoweth and W.O. Weigle. Potentiation of the primary humoralimmune response in vitro by C5a anaphylatoxin. J. Immunol. 129:70,1982.32. Weigle, W. O., E. L. Morgan, M. G. Goodman, D. E. Chenoweth and T. E. Hugli.Modulation of the immune response by anaphylatoxin in the microenvironment of theinteracting cells. Fed. Proc. 41:3099, 1982.33. Goodman, M.G. and W.O. Weigle. Polyclonal activation of B lymphocytes and its role inself/non-self discrimination. In B Lymphocytes Today. (J.R. Inglis, ed.) ElsevierBiomedical Press, Amsterdam, p. 63,1982.34. Chenoweth, D.E. and M.G. Goodman. The C5a receptor of neutrophils and macrophages. InAgents and Actions, Vol. 12 (H.U. Keller, ed.) Birkhauser Verlag, Inc., pp. 252-273, 1983.35. Goodman, M. G., D. E. Chenoweth and W. O. Weigle. Induction of interleukin-1 secretionand enhancement of humoral immunity by binding of human C5a to macrophage surface C5areceptors. J. Exp. Med. 156:912, 1982.36. Goodman, M.G. and W.O. Weigle. Bromination of guanosine and cyclic GMP confers10

esistance to metabolic processing by B cells. J. Immunol 129:2715, 1982.37. Goodman, M.G. and W.O. Weigle. Activation of lymphocytes by a thiol-derivatizednucleoside: characterization of cellular parameters and responsive subpopulations. J.Immunol. 130:551,1983.38. Goodman, M.G. and W.O. Weigle. The role of regulatory components from resident Tlymphocytes in polyclonal B cell activation. In Cellular Recognition. UCLA Symposium onMolecular & Cellular Biology, New Series, Vol. 3 (W.A. Frazier, L. Glaser and D.I.Gottlieb, eds.) Alan R. Liss, Inc., New York, p. 675, 1982.39. Goodman, M.G. and W.O. Weigle. Derivatized guanine nucleosides: a new class of adjuvantfor in vitro antibody responses. J. Immunol. 130:2580,1983.40. Goodman, M.G. and W.O. Weigle. T cell-replacing activity of C8-derivatized guanineribonucleosides. J. Immunol. 130:2042, 1983.41. Goodman, M. G. and W. O. Weigle. Manifold amplification of in vivo immunity in normaland immunodeficient mice by ribonucleosides derivatized at C8 of guanine. Proc. Natl. Acad.Sci. USA. 80:3452,1983.42. Goodman, M.G. and W.O. Weigle. Human C5a induces secretion of interleukin-1 bymacrophages. In 15th Proceedings of International Leucocyte Culture Conference (J.W.Parker and R.L. O'Brien, eds.) John Wiley & Sons Ltd., New York, p. 311,1983.43. Wolfert, R.L., M.G. Goodman and W.O. Weigle. Demonstration of activation-specificinteractions among B lymphocyte membrane proteins by a photoreactive cross-linking agent.J. Immunol. 132:2703, 1984.44. Weigle, W.O., M.G. Goodman, E.L. Morgan and T.E. Hugli. Regulation of immune responseby components of the complement cascade and their activated fragments. Springer Sem.Immunopathol. 6:173, 1983.45. Goodman, M.G. Immunobiologic properties of the C8-derivatized guanine ribonucleosides.Biomedicine and Pharmacotherapy 37:344, 1983.46. Goodman, M.G. and W.O. Weigle. Intracellular lymphocyte activation and carrier-mediatedtransport of CS-substituted guanine ribonucleosides. Proc. Natl. Acad. Sci. USA 81:862,1984.47. Goodman, M.G. Monokine generation as a consequence of binding of human C5aanaphylatoxin to specific cell surface receptors. Lymphokine Research 3:7, 1984.48. Goodman, M.G. and W.O. Weigle. Regulation of B lymphocyte proliferative responses by11

arachidonate metabolites: Effects on membrane-directed versus intracellular activators. J.Allergy & Clin. Immunol. 74:418, 1984.49. Goodman, M. G. Inductive and differentiative signals delivered by C8-substituted guanineribonucleosides. Immunology Today 5:319, 1984.50. Wolfert, R. L., M. G. Goodman and W. O. Weigle. Lymphocyte function and plasmamembrane protein association. In 15th Proceedings of International Leukocyte CultureConference (J.W. Parker and R.L. O'Brien, eds.) John Wiley and Sons Ltd., New York, p.465,1983.51. Goodman, M.G. and W.O. Weigle. Mechanism of 8-mercaptoguanosine mediatedadjuvanticity: Roles of clonal expansion and cellular recruitment. J.Immunol 133:2910,1984.52. Goodman, M.G. and W.O. Weigle. Dissociation of inductive and differentiative signalstransmitted by CS-substituted guanine ribonucleosides to B cells from SJL mice. J. Immunol134:91,1985.53. Scheuer, W. V., M.G. Goodman, D.E. Parks and W.O. Weigle. Enhancement of the in vivoantibody response by an 8-derivatized guanine nucleoside. Cell Immunol 91:294,1985.54. Goodman, M. G. and W. O. Weigle. Restoration of humoral immunity in vitro inimmunodeficient aging mice by C8-derivatized guanine ribonucleosides. J. Immunol134:3808, 1985.55. Goodman, M.G. Demonstration of T cell-dependent and T cell-independent components of8-mereaptoguanosine-mediated adjuvanticity. Proc.Soc.Exper.Biol.Medicine. 179: 479,198556. Strauss, P.R., J.F. Henderson and M.G. Goodman. Nucleosides and lymphocytes-Anoverview. Proc. Soc. Exp. Biol Med. 179:413, 1985.57. Scheuer, W.V., M.G. Goodman, D.E.Parks, and W.O.Weigle. Active transformation oftolerogenic to immunogenic signals in T and B cells by 8-bromoguanosine. J. Immunol 135:2962,1985.58. Wolfert, R.L., M.G. Goodman, and W.O.Weigle. Molecular associations of class II MHCantigens in mitogen-stimulated B cells. J. Immunol 135: 1668, 1985.59. Goodman, M.G., and W.O.Weigle. Enhancement of the human antibody response by CSsubstitutedguanine ribonucleosides in synergy with interleukin 2. J. Immunology 135: 3284,1985.60. Goodman, M.G. and W.O. Weigle. Enhancement of T cell proliferation and differentiationby 8-mercaptoguanosine. In Purine and Pyrimidine Metabolism in Man...V (W.L. Nyhan,12

L.F. Thompson and R.W.E. Watts, eds.) Plenum Publishing Corp., p. 443,1986.61. Goodman, M.G. and W.O. Weigle. Antigen-specific enhancement of the human antibodyresponse by a substituted nucleoside. In Purine and Pyrimidine Metabolism in Man...V(W.L. Nyhan, L.F. Thompson and R.W.E. Watts, eds.) Plenum Publishing Corp., p. 451,1986.62. Goodman, M.G. Mechanism of synergy between T cell signals and C8-substituted guaninenucleosides in humoral immunity: B-lymphotropic cytokines induce responsiveness to 8-mercaptoguanosine. J. Immunol. 136: 3335, 1986.63. Goodman, M.G., and W.J. Hennen. Distinct effects of dual substitution on inductive anddifferentiative activities of C8-substituted guanine ribonucleosides. Cell. Immunol. 102:395-402,1986.64. Goodman, M.G. and R.L. Wolfert. Activation-specific interactions among B-lymphocyteplasma membrane proteins. Immun. Res. 5:71, 1986.65. Goodman, M.G. Regulation of B cell activation by prostaglandins: Cell cycle-specificeffects on activation by anti-immunoglobulin and 8-mercaptoguanosine. J. Immunol.137:3753-3757, 1986.66. Goodman, M.G. Interaction between cytokines and 8-mercaptoguanosine in humoralimmunity: Synergy with interferon. J. Immunol. 139:142,1987.67. Weigle, W.O., M.L. Thoman and M.G. Goodman. Augmentation of the antibody responsein aged mice with an 8-derivatized guanosine nucleoside and its effect on immunologicalmemory. Cell. Immunol. 109:332,1987.68. Weigle, W.O., M.L. Thoman and M.G. Goodman. The effect of aging on the induction oftolerance in a subpopulation of B lymphocytes. Cell. Immunol. 111:253,1988.69. Goodman, M.G. Induction of interleukin 1 activity from macrophages by direct interactionwith C8-substituted guanine ribonucleosides. International J. Immunopharmacol. 10: 579,1988.70. Goodman, M.G. Role of salvage and phosphorylation in the immunostimulatory activity ofC8-substituted guanine ribonucleosides. J. Immunol. 141: 2394, 1988.71. Weigle, W.O., L.C.Gahring, C.G.Romball, and M.G.Goodman. The effect of lipopolysaccharidedesensitization on the regulation of in vivo induction of immunologic tolerance and13

antibody production and in vitro release of IL-1. J. Immunol 142: 1107,1989.72. Goodman, M.G. Demonstration of receptors specific for 7,8-disubstituted guanineribonucleosides in murine B lymphocytes. J. Biol. Chem. 265:22467,1990.73. Goodman, M.G., and D.M. Cherry. Ligand binding sites for a synthetic B cell growth anddifferentiation factor. Cell. Immunol. 123:417,1989.74. Goodman, M. G., L. Speizer, G. Bokoch, J. Kanter, and L. L. Bnmton. Activity of anintracellular lymphocyte stimulator is independent of G-protein interactions, [Ca2+]j elevation,phosphoinositide hydrolysis, and protein kinase C translocation. J. Biol. Chem. 265:12248,1990.75. Goodman, M.G. B lymphocytes from hyporesponsive SJL mice contain aberrant nucleosidereceptors. Cell. Immunol 129: 377, 1990.76. Goodman, M.G., S. Gupta, M.E. Rosenthale, R.J. Capetola, S.C. Bell, and W.O. Weigle.Protein kinase C independent restoration of specific immune responsiveness in commonvariable immunodeficiency. Clinical Immunology and Immunopathology 59:26,1991.77. Goodman, M.G. Cellular and biochemical studies of substituted guanine ribonucleosideimmunostimulants. Immunopharmacol. 21:51. 1991.78. Pope, B.L., J. Sigindere, E. Chourmouzis, and M.G. Goodman. 7-allyl-8-oxoguanosine(loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in miceimmunized with a B16 tumor vaccine. Cancer Immunol. Immunother. 38:83,1994.79. Chen, R., M. G. Goodman, D. Argentieri, S. C. Bell, L. E. Burr, J. Come, J. H. Goodman,D.H. Klaubert, BE Maryanoff, B.L. Pope, MS Rampulla, MR Schott, and AB Reitz.Guanosine deriv-atives as immunostimulants. Discovery of loxoribine. Nucleosides &Nudeotides 13:551, 199480. Goodman, M. G., and J. H. Goodman. Topology of the loxoribine binding site: studies withinactive loxoribine analogues. J. Immunol, 153: 4081-4087,1994.81. Pope, B.L., E. Chourmouzis, J.P. Maclntyre, S. Lee, and M.G. Goodman. Murine strainvariation in the natural killer cell and proliferative responses to the immunostimulatorycompound 7-allyl-8-oxoguanosine: role of cytokines. Cell. Immunol. 159:194, 1994.82. A.B. Reitz, M.G. Goodman, B. Pope, L. Burr, E. Chourmouzis, J. Come, D. Klaubert, B.Maryanoff, M.E. McDonnell, M.S. Rampulla, M.R. Schott, J.H. Goodman, and R. Chen.Small-molecule immunostimulants: Synthesis and activity of 7,8-disubstituted guanosinesand structurally related compounds. J. Med. Chem. 37:3561,1994.14

83. Goodman, M. G., S. Wormsley, J. C. Spinosa, and L.D. Piro. Loxoribine induces ChronicLymphocytic Leukemia B cells to traverse the cell cycle. Blood, 84:3457-3464,1994.84. McKee, D., M.G. Goodman, and L.D. Piro. The Interferons in Hematological Malignancies.Expert Opinion in Investigational Drugs, 13:1, 1994.85. Pope, B.L., E. Chourmouzis, S. Lee, and M.G. Goodman. Enhancement of immunostimulatoryactivity by dual substitution of CS-substituted guanine ribonucleosides:correlation with increased cytokine secretion. J. Immunotherapy, 17:98-108,1995.86. Rivas, A., Tintle, L., Argentieri, D., Kimball, E., Goodman, M., Anderson, D., Capetola, R.,Quimby, F. A primary immunodeficiency syndrome in Shar-pei dogs. Clin. Immunol.Immunopath., 74:243-251,1995.87. Pope, B. L., J. P. Maclntyre, E. Kimball, S. Lee, L. Zhou, R. Gareth, and M. G. Goodman.The immunostimulatory compound 7-allyl-8-oxoguanosine (Loxoribine) induces a distinctsubset of murine cytokines. Cell. Immunol. 162:333-339,1995.88. Goodman, M.G. A new approach to vaccine adjuvants: Immunopotentiation by intracellularT helper-like signals transmitted by Loxoribine. In "Vaccine Design: the subunit andadjuvant approach", M. F. Powell and M.J. Newman, Eds. Plenum Press, New York, N.Y.pp. 581-609,1995.89. Pope, B.L. and M. G. Goodman. Synthetic guanine ribonucleosides as immunostimulants.In "Immimopharmaceuticals", E. Kimball, Ed. CRC Press, Boca Raton, FL. pp. 167-192,1995.90. Goodman, M.G., A.B. Reitz, R. Chen, M.D. Bobardt, J.H. Goodman, and B.L.Pope.Selective modulation of elements of the immune system by low molecular weight nucleosides.J. Pharmacology and Experimental Therapeutics, 274:1552, 1995.91. Goodman, M.G., S. Wormsley, L. Piro, A. Saven, and J. Spinosa. New perspectives on theapproach to Chronic Lymphocytic Leukemia. Leukemia andLymphoma, 18:179, 1995.92. Goodman, M.G., Bobardt, M.C., and Goodman, J.H. B cell receptor-mediated signalingdespite protein tyrosine kinase disruption: Signal salvage by 7-allyl-8-oxoguanosine.Submitted for publication.93. Goodman, M.G., Strahl, D.M., Bobardt, M.D., M. McDonald, A. B. Reitz and J. H.Goodman. Initial characterization of proteins mediating B cell activation by 7,8-disubstitutedguanine ribonucleosides. Submitted for publication.15

94. Elemer, G. S., M. G. Goodman, and T. S. Edgington. Activated

11. Goodman, M.G. and W.O. Weigle. Role of cyclic GMP in lymphocyte activation by abrominated nucleoside analogue. Fed. Proc. 41:491,1982.12. Goodman, M.G. and W.O. Weigle. Human C5a induces secretion of interleukin-1 bymacrophages. 15th International Leucocyte Culture Conference. Immunobiology 163:117,1982.13. Wolfert, R.L., M.G. Goodman and W.O. Weigle. Lymphocyte function and plasmamembrane protein association. 15th International Leucocyte Culture Conference.Immunobiology 163:221, 1982.14. Wolfert, R.L., M.G. Goodman and W.O. Weigle. Membrane protein complexes in Blymphocyte activation. Fed. Proc. 42:557, 1983.15. Goodman, M.G. and W.O. Weigle. T cell-like inductive signals from C8-derivatized guanineribonucleosides. J. Cell Biochem. Suppl. 7B:59,1983.16. Scheuer, W. V., M.G. Goodman, D.E. Parks and W.O. Weigle. Enhancement of antibodyresponses by derivatized guanine ribonucleosides in vivo. Fed. Proc. 43:1425,1984.17. Goodman, M.G. and W.O. Weigle. Opposing regulatory mechanisms for B cell activation asmediated by cyclooxygenase and lipoxygenase products of arachidonic acid. UCLASymposium. 1984.18. Goodman, M.G. and W.O. Weigle. Cellular recruitment versus clonal expansion in 8-mercaptoguanosine-mediated adjuvanticity Fed. Proc. 44:975,1985.19. Wolfert, R.L., M.G. Goodman and W.O. Weigle. Molecular associations of la antigens in Bcell activation. Fed. Proc. 44:1293, 1985.20. Scheuer, W.V., M.G. Goodman, D.E. Parks and W.O. Weigle. Interference by 8-bromoguanosine with tolerance induction and tolerance termination. Fed. Proc. 44:1711,1985.21. Goodman, M.G. and W.O. Weigle. Enhancement of T cell proliferation and differentiationby 8-mercaptoguanosine. Ped. Res. 19:755, 1985.22. Goodman, M.G. and W.O. Weigle. Antigen-specific enhancement of the human antibodyresponse by a substituted nucleoside. Ped. Res. 19:755, 1985.23. Goodman, M.G. Interaction of distinct soluble factors to induce specific antibody secretion.J.CellBiol. 10A:86, 1986.17

24. Goodman, M.G. Role of interferon and other cytokines in synergy with 8-mercaptoguanosine. J. Cell. Biochem. Suppl. 12B: 108,1988.25. Goodman, M.G. Demonstration of two classes of receptor specific for C8 substitutedguanine ribonucleosides. FASEBJ. 2:A1649,1988.26. Goodman, M.G. Ligand binding sites for a synthetic B cell growth and differentiation factor.19th International Leukocyte Culture Conference, p. 180, 1988.27. Goodman, M.G., L. Speizer, G. Bokoch, and L.L. Brunton. Circumvention oftransmembrane signaling by 7m8oGuo. FASEBJ. 3:A1298, 1989.28. Cherry, D.M. and M.G. Goodman. Aberrant nucleoside receptors in hyporesponsive SJLmice. FASEBJ. 3:A1111, 1989.29. Argentieri, D.C., M.G. Goodman, D.M. Ritchie, D.W. Anderson, R.J. Capetola and M.E.Rosenthale. Immunoactivator properties of RWJ 21757, a substituted guanosine. FASEB J.4:A1724,1990.30. Goodman, M.G., S. Gupta and W.O. Weigle. C-Kinase independent restoration of specificimmune responsiveness in common variable immunodeficiency. FASEBJ. 4:A1700,1990.31. Goodman, M.G. and L.D. Piro. Induction of proliferative activity by Loxoribine in cells frompatients with chronic lymphocytic leukemia. Blood 70, Suppl. 1:437a. 1991.32. Goodman, M.G., R. Abels, D. Anderson, R. Capetola, B.Pope, and I.Smith. Loxoribine: adisubstituted guanosine with adjuvant activity. AIDS research and human retroviruses, Suppl.1:895,1993.33. Goodman, M., S. Wormsley, J. Spinosa, and L. Piro. Induction of CLL B cell activation andsensitivity to cycle-active cytotoxic agents. J.Immunol 152:3213,1994.34. Goodman, M.G., D. Strahl, M. Bobardt, and J. Goodman. Intracellular nucleoside-bindingproteins with specificity for loxoribine. FASEBJ. 9:A812, 1995.35. Bobardt, M., J. Goodman, and M. Goodman. B cell receptor-mediated signaling despite PTKdisruption. 9th International Congress of Immunology, p.683, #4054, 1995.36. Pope, B., E. Chourmouzis, J. Maclntyre, S. Lee, and M. Goodman. Role of cytokines in NKcell and proliferative responses to Loxoribine. 9th International Congress of Immunology,p. 120, #711,1995.37. Barone, R.M., Shiftan, TA, Harrison JA, Saleh, F, Kogler, JW, Redfera, CH, Goodman, M,18

McKee, D, Earth, N, Guthiel, J. Complete Cytoreductive Surgery (CCS) combined withimmediate postoperative intraperitoneal chemotherapy (IPIPC) with FUDR and Cisplatin forrecurrent stage III ovarian carcinoma. ASCO Proceedings, p. 3156; 2000.19

SELECTED PRESENTATIONS1. World Health Organization: Geneva, Switzerland, 1990. Immune-enhancing activities of 7,8-disubstituted guanine ribonucleoside structural analogues: relevance to vaccines forcommunicable diseases.2. Sandoz Pharmaceuticals Ltd: Basel, Switzerland, 1995. Application of selectively B-cellimmuno-suppressive substituted guanine nucleoside analogues to treatment of chronic graftversus-hostdisease.3. Johnson & Johnson Biosciences Advisory Committee: La Jolla, CA., 1992. Clinicalapplications and mechanism of action of Loxoribine.4. Johnson & Johnson Biosciences Advisory Committee: La Jolla, CA., 1991.Immimobiological activity of the class of substituted guanine ribonucleosides.5. Ortho Pharmaceutical Corp.: Raritan, NJ., 1990. Recent developments in the synthesis andactivity of substituted guanine ribonucleosides.6. Federation of the American Societies for Experimental Biology: New Orleans, LA, 1990. C-Kinase independent restoration of specific immune responsiveness in common variableimmunodeficiency.7. La Jolla Pharmaceuticals: La Jolla, CA. 1991. Substituted guanine nucleosides andautoimmunity.8. Ortho Pharmaceutical Corp.: Toronto, Ontario. 1991. New synthetic structures and backbonesfor oligomeric polynucleotides containing substituted guanine bases: effects onimmunoenhancing activity.9. AIDS research and human retroviruses: Washington, D.C., 1993. Loxoribine: a disubstitutedguanosine with adjuvant activity.10. The Scripps Clinic, Department of Allergy and Immunology: La Jolla, CA., 1994.Immunobiological activities of Loxoribine.11. Federation of the American Societies for Experimental Biology: Anaheim, CA, 1994.Induction of CLL B cell activation and sensitivity to cycle-active cytotoxic agents.12. The Scripps Research Institute, Department of Immunology Retreat: Rancho Valencia, CA.1994. B lymphocyte signaling and stimulation.13. John Wayne Cancer Institute, Santa Monica, CA, 1995: Heightened efficacy of cancer vaccinesin combination with 7,8-disubstituted guanine ribonucleoside structural analogues.14. 9th International Congress of Immunology: San Francisco, CA., 1995. Role of cytokines inNK cell and proliferative responses to Loxoribine.15. Federation of the American Societies for Experimental Biology: Boston, MA, 1995.Intracellular nucleoside-binding proteins with specificity for loxoribine.16. The Scripps Research Institute, La Jolla, CA. 1995: Hematology/Oncology Fellows lecture.17. Genzyme Corp: Boston, MA, 1995. Immunological activities of 7,8-disubstituted guanineribonucleoside structural analogues.18. St. John's Lutheran Hospital, Libby, MT. 1997. Significance of serologic tumor markers inbreast cancer.19. Kalispell Regional Medical Center, Kalispell, MT. 1998. Nursing CME lecture: Update on20

new and developing treatments for Chronic Lymphocytic Leukemia.20. St. Joseph's Hospital, Poison, MT. 1999. Recent developments in the diagnosis and treatmentof Chronic Lymphocytic Leukemia.21. Kalispell Regional Medical Center, Kalispell, MT. 2007. Breast Cancer AwarenessSymposium: New developments in biologic treatments for breast cancer patients.22. Kalispell Regional Medical Center, Kalispell, MT. 2008. Update and discussion of multiplemyeloma.21